182 related articles for article (PubMed ID: 20454974)
1. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
[TBL] [Abstract][Full Text] [Related]
2. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
Yurkovetsky ZR; Kirkwood JM; Edington HD; Marrangoni AM; Velikokhatnaya L; Winans MT; Gorelik E; Lokshin AE
Clin Cancer Res; 2007 Apr; 13(8):2422-8. PubMed ID: 17438101
[TBL] [Abstract][Full Text] [Related]
3. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
Grimm EA; Smid CM; Lee JJ; Tseng CH; Eton O; Buzaid AC
Clin Cancer Res; 2000 Oct; 6(10):3895-903. PubMed ID: 11051235
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
6. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C.
Jia HY; Du J; Zhu SH; Ma YJ; Chen HY; Yang BS; Cai HF
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):378-82. PubMed ID: 14607710
[TBL] [Abstract][Full Text] [Related]
7. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
Abe S; Narita R; Matsuhashi T; Oto T; Tabaru A; Otsuki M
Eur J Gastroenterol Hepatol; 2008 May; 20(5):373-8. PubMed ID: 18403937
[TBL] [Abstract][Full Text] [Related]
8. Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.
Vihinen P; Tervahartiala T; Sorsa T; Hansson J; Bastholt L; Aamdal S; Stierner U; Pyrhönen S; Syrjänen K; Lundin J; Hernberg M
Cancer Immunol Immunother; 2015 Feb; 64(2):173-80. PubMed ID: 25319807
[TBL] [Abstract][Full Text] [Related]
9. Patterns of failure in patients with malignant melanoma treated with high-dose interferon-alpha2b in the adjuvant setting.
Schachter J; Brenner B; Fenig E; Gutman R; Sulkes A; Gutman H
Melanoma Res; 2003 Feb; 13(1):93-6. PubMed ID: 12569291
[TBL] [Abstract][Full Text] [Related]
10. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.
Bien E; Rapala M; Krawczyk M; Balcerska A
J Cancer Res Clin Oncol; 2010 Feb; 136(2):293-305. PubMed ID: 19693535
[TBL] [Abstract][Full Text] [Related]
11. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis.
Bal A; Unlu E; Bahar G; Aydog E; Eksioglu E; Yorgancioglu R
Clin Rheumatol; 2007 Feb; 26(2):211-5. PubMed ID: 16583185
[TBL] [Abstract][Full Text] [Related]
12. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back.
Berghella AM; Pellegrini P; Del Beato T; Marini M; Tomei E; Adorno D; Casciani CU
Cancer Immunol Immunother; 1998 Jan; 45(5):241-9. PubMed ID: 9439647
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
Espinosa E; Soriano V; Malvehy J; Berrocal A; Martínez de Prado P; Quindós M; Soria A; Márquez-Rodas I; Palacio I; Cerezuela P; López-Vivanco G; Alonso L; Samaniego E; Ballesteros A; Puértolas T; Díaz-Beveridge R; de la Cruz-Merino L; López Castro R; López López R; Stevinson K; Del Barrio P; Tornamira MV; Guillém V; Martín-Algarra S
Melanoma Res; 2016 Jun; 26(3):278-83. PubMed ID: 26958991
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Eigentler TK; Gutzmer R; Hauschild A; Heinzerling L; Schadendorf D; Nashan D; Hölzle E; Kiecker F; Becker J; Sunderkötter C; Moll I; Richtig E; Pönitzsch I; Pehamberger H; Kaufmann R; Pföhler C; Vogt T; Berking C; Praxmarer M; Garbe C;
Ann Oncol; 2016 Aug; 27(8):1625-32. PubMed ID: 27287206
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of IL-2, IL-1 alpha, TNF-alpha, and soluble receptor of IL-2 in HIV-1-infected patients.
Scott-Algara D; Vuillier F; Marasescu M; de Saint Martin J; Dighiero G
AIDS Res Hum Retroviruses; 1991 Apr; 7(4):381-6. PubMed ID: 1676897
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum cytokines IL-1beta, sIL-2R, IL-6, TNF-alpha, and IFN-v in acute coronary syndrome.
Wang YN; Che SM; Ma AQ
Chin Med Sci J; 2004 Jun; 19(2):120-4. PubMed ID: 15250248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
